Publication | Open Access

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

Endocrine OncologyBreast OncologyMedicinePreplanned Interim AnalysisPharmacologyGynecologyEndocrine TherapyBreast CancerPharmacotherapyCancer TreatmentEndocrinologyOncologyRadiation OncologyEndocrine-related Cancer